Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | PLX-61639 |
| Synonyms | |
| Therapy Description |
PLX-61639 is a selective SMARCA2 degrader, which potentially inhibits cell proliferation and growth of SMARCA4-mutant tumors (Cancer Res (2025) 85 (8_Supplement_1): 1653). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| PLX-61639 | PLX61639|PLX 61639 | PLX-61639 is a selective SMARCA2 degrader, which potentially inhibits cell proliferation and growth of SMARCA4-mutant tumors (Cancer Res (2025) 85 (8_Supplement_1): 1653). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07284186 | Phase I | PLX-61639 | First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | 0 |